Hyphens Pharma International Ltd. (SG:1J5) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hyphens Pharma International Ltd. reported a 22.1% increase in revenue for the first nine months of 2024, reaching S$143.5 million, driven by strong sales in Singapore and Malaysia. Despite a 12.1% rise in gross profit for the third quarter, net profit after tax slightly declined due to increased distribution and administrative costs. The company remains optimistic about its financial growth, bolstered by favorable currency exchange rates.
For further insights into SG:1J5 stock, check out TipRanks’ Stock Analysis page.

